依帕司他片在老年2型糖尿病肾病患者治疗中的应用效果

Practical effect of epalrestat tablets in the treatment of elderly patients with type 2 diabetic nephropathy

目的探讨依帕司他片在老年2型糖尿病肾病患者治疗中的应用效果。方法86例老年2型糖尿病肾病患者作为研究对象,以随机数字表法分为对照组和观察组,每组43例。对照组采取常规医治方法,观察组患者在对照组基础上给予依帕司他片治疗。对比两组治疗前后肾功能指标[尿白蛋白(Alb)、尿白蛋白排泄率(UAE)、血清同型半胱氨酸(Hcy)、血清胱抑素C(CysC)]、治疗前后炎症反应指标[白细胞介素-8(IL-8)、单核细胞趋化蛋白-1(MCP-1)、细胞间粘附分子-1(ICAM-1)]、治疗前后氧化应激指标[活性氧(ROS)、晚期蛋白氧化产物(AOPPs)、总超氧化物歧化酶(T-SOD)]。结果治疗后,观察组Alb为(15.30±3.06)mg/L、UAE为(65.31±9.20)μg/min、Hcy为(13.14±1.97)μmol/L、CysC为(1.68±0.32)mg/L,均低于对照组的(18.24±3.38)mg/L、(72.51±9.36)μg/min、(14.60±2.18)μmol/L、(2.02±0.41)mg/L,差异具有统计学意义(P<0.05)。治疗后,观察组IL-8为(29.87±5.90)pg/ml、MCP-1为(168.91±18.64)pg/ml、ICAM-1为(13.26±2.70)ng/ml,均低于对照组的(35.94±6.82)pg/ml、(186.75±23.71)pg/ml、(15.37±3.02)ng/ml,差异具有统计学意义(P<0.05)。治疗后,观察组的ROS(256.70±51.36)μmol/L、AOPPs(30.91±6.10)μmol/L均显著低于对照组的(311.54±71.60)、(38.47±7.30)μmol/L,TSOD(71.35±8.90)μg/ml显著高于对照组的(62.67±8.41)μg/ml,差异具有统计学意义(P<0.05)。结论老年2型糖尿病肾病患者应用依帕司他片治疗的临床疗效显著,可改善患者的血糖及肾功能水平,进一步促进生活质量的改善;因此,值得在临床治疗工作中推广及应用。

Objective To discuss the practical effect of epalrestat tablets in the treatment of elderly patients with type 2 diabetic nephropathy.Methods A total of 86 elderly patients with type 2 diabetic nephropathy as study subjects were divided into observation group and control group according to random numerical table,with 43 cases in each group.The control group was treated with conventional medicine,and the observation group was treated with epalrestat tablets based on the control group.The renal function indexes[urinary albumin(Alb),urinary albumin excretion rate(UAE),serum homocysteine(Hcy),serum cystatin C(Cys C)],inflammation indexes[interleukin-8(IL-8),monocyte chemoattractant protein-1(MCP-1),intercellular adhesion molecule-1(ICAM-1)],oxidative stress indicators[reactive oxygen species(ROS),advanced oxidation protein products(AOPPs),total superoxide dismutase(T-SOD)]were compared between the two groups before and after treatment.Results After treatment,the Alb(15.30±3.06)mg/L,UAE(65.31±9.20)μg/min,Hcy(13.14±1.97)μmol/L,and Cys C(1.68±0.32)mg/L of the observation group were lower than(18.24±3.38)mg/L,(72.51±9.36)μg/min,(14.60±2.18)μmol/L,(2.02±0.41)mg/L of the control group,and the difference was statistically significant(P<0.05).After treatment,the IL-8(29.87±5.90)pg/ml,MCP-1(168.91±18.64)pg/ml,and ICAM-1(13.26±2.70)ng/ml of the observation group were lower than(35.94±6.82)pg/ml,(186.75±23.71)pg/ml and(15.37±3.02)ng/ml of the control group,and the difference was statistically significant(P<0.05).After treatment,the ROS(256.70±51.36)μmol/L and AOPPs(30.91±6.10)μmol/L of the observation group were significantly lower than(311.54±71.60),(38.47±7.30)μmol/L of the control group,and the TSOD(71.35±8.90)μg/ml was higher than(62.67±8.41)μg/ml of the control group.All the difference was statistically significant(P<0.05).Conclusion Epalrestat tablets has significant clinical efficacy on elderly patients with diabetic nephropathy,and it can improve the blood glucose and renal function and further improve the quality of life of the patients.Therefore,it is worth popularizing and applying in clinical treatment.